292 related articles for article (PubMed ID: 11144928)
21. Detection of residual tumor cells in bladder biopsy specimens: pitfalls in the interpretation of cytokeratin stains.
Tamas EF; Epstein JI
Am J Surg Pathol; 2007 Mar; 31(3):390-7. PubMed ID: 17325480
[TBL] [Abstract][Full Text] [Related]
22. Discriminatory immunohistochemical staining of urothelial carcinoma in situ and non-neoplastic urothelium: an analysis of cytokeratin 20, p53, and CD44 antigens.
McKenney JK; Desai S; Cohen C; Amin MB
Am J Surg Pathol; 2001 Aug; 25(8):1074-8. PubMed ID: 11474293
[TBL] [Abstract][Full Text] [Related]
23. E-cadherin expression during urothelial carcinogenesis induced by N-butyl-N-(4-hydroxybutyl) nitrosamine in rats.
Oliveira PA; Colaço A; De la Cruz LF; Lopes P; Lopes C
J Exp Clin Cancer Res; 2006 Sep; 25(3):425-32. PubMed ID: 17167984
[TBL] [Abstract][Full Text] [Related]
24. High-grade papillary urothelial carcinoma of the urinary tract: a clinicopathologic analysis of a post-World Health Organization/International Society of Urological Pathology classification cohort from a single academic center.
Chaux A; Karram S; Miller JS; Fajardo DA; Lee TK; Miyamoto H; Netto GJ
Hum Pathol; 2012 Jan; 43(1):115-20. PubMed ID: 21820145
[TBL] [Abstract][Full Text] [Related]
25. Immunoreactivity of p63 in monolayered and in vitro stratified human urothelial cell cultures compared with native urothelial tissue.
Feil G; Maurer S; Nagele U; Krug J; Bock C; Sievert KD; Stenzl A
Eur Urol; 2008 May; 53(5):1066-72. PubMed ID: 17980954
[TBL] [Abstract][Full Text] [Related]
26. Expression of cathepsin D in urothelial carcinoma of the urinary bladder: an immunohistochemical study including correlations with extracellular matrix components, CD44, p53, Rb, c-erbB-2 and the proliferation indices.
Ioachim E; Charchanti A; Stavropoulos N; Athanassiou E; Bafa M; Agnantis NJ
Anticancer Res; 2002; 22(6A):3383-8. PubMed ID: 12530091
[TBL] [Abstract][Full Text] [Related]
27. Urothelial neoplasms in patients 20 years or younger: a clinicopathological analysis using the world health organization 2004 bladder consensus classification.
Fine SW; Humphrey PA; Dehner LP; Amin MB; Epstein JI
J Urol; 2005 Nov; 174(5):1976-80. PubMed ID: 16217372
[TBL] [Abstract][Full Text] [Related]
28. Association of TSC1/hamartin, 14-3-3sigma, and p27 expression with tumor outcomes in patients with pTa/pT1 urothelial bladder carcinoma.
Mhawech-Fauceglia P; Alvarez V; Fischer G; Beck A; Herrmann FR
Am J Clin Pathol; 2008 Jun; 129(6):918-23. PubMed ID: 18480009
[TBL] [Abstract][Full Text] [Related]
29. FGFR3 mutations and a normal CK20 staining pattern define low-grade noninvasive urothelial bladder tumours.
van Oers JM; Wild PJ; Burger M; Denzinger S; Stoehr R; Rosskopf E; Hofstaedter F; Steyerberg EW; Klinkhammer-Schalke M; Zwarthoff EC; van der Kwast TH; Hartmann A
Eur Urol; 2007 Sep; 52(3):760-8. PubMed ID: 17240035
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of p53 nuclear accumulation in low- and high-grade (WHO/ISUP classification) transitional papillary carcinomas of the bladder for tumor recurrence and progression.
Vardar E; Gunlusoy B; Minareci S; Postaci H; Ayder AR
Urol Int; 2006; 77(1):27-33. PubMed ID: 16825812
[TBL] [Abstract][Full Text] [Related]
31. The WHO/ISUP 1998 and WHO 1999 systems for malignancy grading of bladder cancer. Scientific foundation and translation to one another and previous systems.
Busch C; Algaba F
Virchows Arch; 2002 Aug; 441(2):105-8. PubMed ID: 12189498
[TBL] [Abstract][Full Text] [Related]
32. Expression of cytokeratin 20 and CD44 protein in upper urinary tract transitional cell carcinoma: cytologic-histologic correlation.
Weaver EJ; McCue PA; Bagley DH; Kovatich AJ; Bibbo M
Anal Quant Cytol Histol; 2001 Oct; 23(5):339-44. PubMed ID: 11693559
[TBL] [Abstract][Full Text] [Related]
33. Comparison of WHO 1973, WHO/ISUP 1998, WHO 1999 grade and combined scoring systems in evaluation of bladder carcinoma.
Bircan S; Candir O; Serel TA
Urol Int; 2004; 73(3):201-8. PubMed ID: 15539837
[TBL] [Abstract][Full Text] [Related]
34. Immunohistochemical expression of CK20, p53, and Ki-67 as objective markers of urothelial dysplasia.
Mallofré C; Castillo M; Morente V; Solé M
Mod Pathol; 2003 Mar; 16(3):187-91. PubMed ID: 12640096
[TBL] [Abstract][Full Text] [Related]
35. Expression of maspin in papillary Ta/T1 bladder neoplasms.
Blandamura S; D'Alessandro E; Giacomelli L; Guzzardo V; Battanello W; Repele M; Ninfo V
Anticancer Res; 2008; 28(1B):471-8. PubMed ID: 18383887
[TBL] [Abstract][Full Text] [Related]
36. Urothelial neoplasms of the urinary bladder occurring in young adult and pediatric patients: a comprehensive review of literature with implications for patient management.
Paner GP; Zehnder P; Amin AM; Husain AN; Desai MM
Adv Anat Pathol; 2011 Jan; 18(1):79-89. PubMed ID: 21169741
[TBL] [Abstract][Full Text] [Related]
37. Papillary urothelial neoplasm of low malignant potential: reliability of diagnosis and outcome.
Campbell PA; Conrad RJ; Campbell CM; Nicol DL; MacTaggart P
BJU Int; 2004 Jun; 93(9):1228-31. PubMed ID: 15180612
[TBL] [Abstract][Full Text] [Related]
38. Urothelial papillary (exophytic) neoplasms.
Bostwick DG; Mikuz G
Virchows Arch; 2002 Aug; 441(2):109-16. PubMed ID: 12189499
[TBL] [Abstract][Full Text] [Related]
39. [New WHO classification of urothelial carcinoma of the urinary bladder].
Helpap B
Verh Dtsch Ges Pathol; 2002; 86():57-66. PubMed ID: 12647352
[TBL] [Abstract][Full Text] [Related]
40. Proliferative status is a risk index for recurrence in primary superficial (pTa/T1) low-grade urothelial bladder carcinoma.
Su JS; Arima K; Hasegawa M; Franco OE; Yanagawa M; Sugimura Y; Kawamura J
Hinyokika Kiyo; 2003 Nov; 49(11):649-58. PubMed ID: 14719452
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
